The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Lipid lowering agents and the endothelium: an update after 4 years.

TitleLipid lowering agents and the endothelium: an update after 4 years.
Publication TypeJournal Article
Year of Publication2012
AuthorsTziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P.
JournalCurr Vasc Pharmacol
Volume10
Issue1
Pagination33-41
Date Published2012 Jan
ISSN1875-6212
KeywordsAnimals, Cardiovascular Agents, Endothelium, Vascular, Fatty Acids, Omega-3, Humans, Hypolipidemic Agents, Risk Factors, Vascular Diseases
Abstract

Endothelial dysfunction represents an important step in the pathogenesis of atherosclerosis. All vascular risk factors can induce endothelial dysfunction, which in turn results in the loss of the protective effects of the endothelium culminating in the development of atherosclerosis. Dyslipidemia is a major vascular risk factor and is associated with endothelial dysfunction. Several studies showed that lipid-lowering agents exert beneficial effects on endothelial function in different populations at increased vascular risk, including patients without dyslipidemia. Therefore, other actions besides lipid-profile modification appear to be implicated in this benefit. However, it is unclear whether the improvement in endothelial function independently contributes to the vascular risk reduction during lipid-lowering treatment (e.g. with statins). It is also unclear whether the assessment of endothelial function would help identify patients who require more aggressive lipid-lowering treatment.

Alternate JournalCurr Vasc Pharmacol
PubMed ID22112353

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.